• Harrow recently re-launched VERKAZIA (cyclosporine ophthalmic emulsion) 0.1% in the US for vernal keratoconjunctivitis, backed by a commercial push around physician education, patient access, and affordability for this serious allergic eye disease that primarily affects children.
• The move reintroduces what has been described as a steroid-sparing therapy option into a market where many pediatric VKC patients remain inadequately controlled and long-term steroid use carries meaningful safety concerns.
• Next, we’ll examine how VERKAZIA’s re-launch as a steroid-sparing option in pediatric VKC may influence Harrow’s broader investment narrative.

Find 46 companies with promising cash flow potential yet trading below their fair value.

Harrow Investment Narrative Recap

To own Harrow, you need to believe its expanding ophthalmic portfolio can offset concentration risk in VEVYE, IHEEZO, and TRIESENCE while the company moves toward profitability. The VERKAZIA re launch supports that diversification story but does not change the fact that near term performance still hinges on execution against ambitious 2026 revenue guidance and on managing high operating costs, which remain the key catalyst and risk, respectively.

The VERKAZIA news sits alongside Harrow’s recent Q1 2026 update, where revenue was US$44.2 million and the company reported a US$27.6 million net loss while reaffirming aggressive full year revenue guidance of US$350–365 million. Together, these announcements frame VERKAZIA less as a standalone driver and more as one of several products that need to contribute meaningfully if Harrow is to close the gap between current losses and its revenue and margin ambitions.

Yet beneath VERKAZIA’s promise, investors should be aware that concentrated reliance on a few products leaves Harrow exposed if...

Harrow’s narrative projects $784.8 million revenue and $246.0 million earnings by 2029. This requires 42.9% yearly revenue growth and a $261.0 million earnings increase from -$15.0 million today.

Uncover how Harrow's forecasts yield a $68.38 fair value, a 104% upside to its current price.

Exploring Other Perspectives

While consensus focuses on concentration risk and execution around VERKAZIA, the most optimistic analysts were already modeling revenue of about US$831.4 million and earnings near US$262 million by 2029, so this launch could either reinforce or challenge those much more upbeat assumptions depending on how the story evolves from here.

Explore 3 other fair value estimates on Harrow - why the stock might be worth over 9x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Harrow research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Harrow research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Harrow's overall financial health at a glance.

Contemplating Other Strategies?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• Outshine the giants: these 15 early-stage AI stocks could fund your retirement.
• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.